{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:22:53Z","timestamp":1771993373469,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00105-023-05148-z","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T09:02:55Z","timestamp":1685955775000},"page":"410-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molekulare Diagnostik des Handekzems","Molecular diagnosis of hand eczema"],"prefix":"10.1007","volume":"74","author":[{"given":"Kristin","family":"Technau-Hafsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Garzorz-Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"5148_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/jdv.18178","volume":"36","author":"S Ziehfreund","year":"2022","unstructured":"Ziehfreund\u00a0S et al (2022) Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021\u2014a two-round Delphi survey among international experts. J\u00a0Eur Acad Dermatol Venereol 36:1467\u20131476. https:\/\/doi.org\/10.1111\/jdv.18178","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5148_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2340\/00015555-2779","volume":"98","author":"M Kolesnik","year":"2018","unstructured":"Kolesnik\u00a0M, Franke\u00a0I, Lux\u00a0A, Quist\u00a0SR, Gollnick\u00a0HP (2018) Eczema in Psoriatico: an important differential diagnosis between chronic allergic contact dermatitis and psoriasis in palmoplantar localization. Acta Derm Venereol 98:50\u201358. https:\/\/doi.org\/10.2340\/00015555-2779","journal-title":"Acta Derm Venereol"},{"key":"5148_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1600-0463.2009.02513.x","volume":"117","author":"AM Cesinaro","year":"2009","unstructured":"Cesinaro\u00a0AM, Nannini\u00a0N, Migaldi\u00a0M, Pepe\u00a0P, Maiorana\u00a0A (2009) Psoriasis vs allergic contact dermatitis in palms and soles: a\u00a0quantitative histologic and immunohistochemical study. APMIS 117:629\u2013634. https:\/\/doi.org\/10.1111\/j.1600-0463.2009.02513.x","journal-title":"APMIS"},{"key":"5148_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13192","author":"JAF Oosterhaven","year":"2018","unstructured":"Oosterhaven\u00a0JAF et\u00a0al (2018) European Surveillance System on Contact Allergies (ESSCA): contact allergies in relation to body sites in patients with allergic contact dermatitis. Contact Derm. https:\/\/doi.org\/10.1111\/cod.13192","journal-title":"Contact Derm"},{"issue":"Suppl 3","key":"5148_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2009.07061.x","volume":"7","author":"TL Diepgen","year":"2009","unstructured":"Diepgen\u00a0TL et al (2009) Guideline on the management of hand eczema ICD-10 Code: L20. L23. L24. L25. L30. J\u00a0Dtsch Dermatol Ges 7(Suppl 3):S1\u201316. https:\/\/doi.org\/10.1111\/j.1610-0387.2009.07061.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"5148_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/jdv.12735","volume":"29","author":"MB Boonstra","year":"2015","unstructured":"Boonstra\u00a0MB, Christoffers\u00a0WA, Coenraads\u00a0PJ, Schuttelaar\u00a0ML (2015) Patch test results of hand eczema patients: relation to clinical types. J\u00a0Eur Acad Dermatol Venereol 29:940\u2013947. https:\/\/doi.org\/10.1111\/jdv.12735","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5148_CR7","doi-asserted-by":"publisher","first-page":"WC04","DOI":"10.7860\/JCDR\/2016\/23994.8884","volume":"10","author":"N Vigneshkarthik","year":"2016","unstructured":"Vigneshkarthik\u00a0N, Ganguly\u00a0S, Kuruvila\u00a0S (2016) Patch test as a\u00a0diagnostic tool in hand eczema. J\u00a0Clin Diagn Res 10:WC4\u2013WC7. https:\/\/doi.org\/10.7860\/JCDR\/2016\/23994.8884","journal-title":"J Clin Diagn Res"},{"key":"5148_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","volume":"32","author":"K Eyerich","year":"2018","unstructured":"Eyerich\u00a0K, Eyerich\u00a0S (2018) Immune response patterns in non-communicable inflammatory skin diseases. J\u00a0Eur Acad Dermatol Venereol 32:692\u2013703. https:\/\/doi.org\/10.1111\/jdv.14673","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5148_CR9","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt\u00a0A et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a\u00a01-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1","journal-title":"Lancet"},{"key":"5148_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg\u00a0A et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437\u2013449. https:\/\/doi.org\/10.1111\/bjd.19574","journal-title":"Br J Dermatol"},{"key":"5148_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14982","author":"JAF Oosterhaven","year":"2019","unstructured":"Oosterhaven\u00a0JAF, Voorberg\u00a0AN, Romeijn\u00a0GLE, de Bruin-Weller\u00a0MS, Schuttelaar\u00a0MLA (2019) Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J\u00a0Dermatol. https:\/\/doi.org\/10.1111\/1346-8138.14982","journal-title":"J Dermatol"},{"key":"5148_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1684\/ejd.2013.2197","volume":"23","author":"Y Umezawa","year":"2013","unstructured":"Umezawa\u00a0Y, Ito\u00a0K, Nakagawa\u00a0H (2013) Palisaded neutrophilic and granulomatous dermatitis in a\u00a0rheumatoid arthritis patient after treatment with adalimumab. Eur J Dermatol 23:910\u2013911. https:\/\/doi.org\/10.1684\/ejd.2013.2197","journal-title":"Eur J Dermatol"},{"key":"5148_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jamadermatol.2017.2826","volume":"153","author":"MJ Sladden","year":"2017","unstructured":"Sladden\u00a0MJ, Sladden\u00a0CS, Gulliver\u00a0WPF (2017) Secukinumab-induced psoriasiform eruption. JAMA Dermatol 153:1194\u20131195. https:\/\/doi.org\/10.1001\/jamadermatol.2017.2826","journal-title":"JAMA Dermatol"},{"key":"5148_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/all.15578","volume":"78","author":"C Broderick","year":"2023","unstructured":"Broderick\u00a0C et\u00a0al (2023) Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: a systematic review. Allergy 78:84\u2013120. https:\/\/doi.org\/10.1111\/all.15578","journal-title":"Allergy"},{"key":"5148_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.23736\/S0392-0488.16.05312-8","volume":"152","author":"M Schiattarella","year":"2017","unstructured":"Schiattarella\u00a0M et al (2017) Chronic hand eczema: is IL-36alpha helpful in diagnosis and classification? G\u00a0Ital Dermatol Venereol 152:578\u2013585. https:\/\/doi.org\/10.23736\/S0392-0488.16.05312-8","journal-title":"G Ital Dermatol Venereol"},{"key":"5148_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3389\/fimmu.2019.01162","volume":"10","author":"AL Buhl","year":"2019","unstructured":"Buhl\u00a0AL, Wenzel\u00a0J (2019) Interleukin-36 in infectious and inflammatory skin diseases. Front Immunol 10:1162. https:\/\/doi.org\/10.3389\/fimmu.2019.01162","journal-title":"Front Immunol"},{"key":"5148_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/jid.2014.532","volume":"135","author":"AM D\u2019Erme","year":"2015","unstructured":"D\u2019Erme\u00a0AM et al (2015) IL-36gamma (IL-1F9) is a\u00a0biomarker for psoriasis skin lesions. J\u00a0Invest Dermatol 135:1025\u20131032. https:\/\/doi.org\/10.1038\/jid.2014.532","journal-title":"J Invest Dermatol"},{"key":"5148_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaci.2018.04.031","volume":"142","author":"A Berekmeri","year":"2018","unstructured":"Berekmeri\u00a0A et al (2018) Detection of IL-36gamma through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema. J\u00a0Allergy Clin Immunol 142:988\u2013991e984. https:\/\/doi.org\/10.1016\/j.jaci.2018.04.031","journal-title":"J Allergy Clin Immunol"},{"key":"5148_CR19","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaci.2018.06.016","volume":"142","author":"TC Chan","year":"2018","unstructured":"Chan\u00a0TC et\u00a0al (2018) Atopic dermatitis in Chinese patients shows TH2\/TH17 skewing with psoriasiform features. J\u00a0Allergy Clin Immunol 142:1013\u20131017. https:\/\/doi.org\/10.1016\/j.jaci.2018.06.016","journal-title":"J Allergy Clin Immunol"},{"key":"5148_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/sj.jid.5700945","volume":"128","author":"J Wenzel","year":"2008","unstructured":"Wenzel\u00a0J et al (2008) Gene expression profiling of lichen planus reflects CXCL9+-mediated inflammation and distinguishes this disease from atopic dermatitis and psoriasis. J\u00a0Invest Dermatol 128:67\u201378. https:\/\/doi.org\/10.1038\/sj.jid.5700945","journal-title":"J Invest Dermatol"},{"key":"5148_CR21","doi-asserted-by":"publisher","first-page":"244ra290","DOI":"10.1126\/scitranslmed.3008946","volume":"6","author":"M Quaranta","year":"2014","unstructured":"Quaranta\u00a0M et\u00a0al (2014) Intraindividual genome expression analysis reveals a\u00a0specific molecular signature of psoriasis and eczema. Sci Transl Med 6:244ra290. https:\/\/doi.org\/10.1126\/scitranslmed.3008946","journal-title":"Sci Transl Med"},{"key":"5148_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1104200","volume":"365","author":"S Eyerich","year":"2011","unstructured":"Eyerich\u00a0S et\u00a0al (2011) Mutual antagonism of T cells causing psoriasis and atopic eczema. N\u00a0Engl J Med 365:231\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa1104200","journal-title":"N Engl J Med"},{"key":"5148_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/jid.2013.394","volume":"134","author":"M Mildner","year":"2014","unstructured":"Mildner\u00a0M et\u00a0al (2014) Epidermal CCL27 expression is regulated during skin development and keratinocyte differentiation. J\u00a0Invest Dermatol 134:855\u2013858. https:\/\/doi.org\/10.1038\/jid.2013.394","journal-title":"J Invest Dermatol"},{"key":"5148_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1462-5822.2010.01559.x","volume":"13","author":"H Muhl","year":"2011","unstructured":"Muhl\u00a0H, Bachmann\u00a0M, Pfeilschifter\u00a0J (2011) Inducible NO synthase and antibacterial host defence in times of Th17\/Th22\/T22 immunity. Cell Microbiol 13:340\u2013348. https:\/\/doi.org\/10.1111\/j.1462-5822.2010.01559.x","journal-title":"Cell Microbiol"},{"key":"5148_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/exd.13077","volume":"25","author":"N Garzorz-Stark","year":"2016","unstructured":"Garzorz-Stark\u00a0N et al (2016) A novel molecular disease classifier for psoriasis and eczema. Exp Dermatol 25:767\u2013774. https:\/\/doi.org\/10.1111\/exd.13077","journal-title":"Exp Dermatol"},{"key":"5148_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/1744666X.2015.996549","volume":"11","author":"N Garzorz","year":"2015","unstructured":"Garzorz\u00a0N, Eyerich\u00a0K (2015) NOS2 and CCL27: clinical implications for psoriasis and eczema diagnosis and management. Expert Rev Clin Immunol 11:167\u2013169. https:\/\/doi.org\/10.1586\/1744666X.2015.996549","journal-title":"Expert Rev Clin Immunol"},{"key":"5148_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00105-021-04774-9","volume":"72","author":"P Bentz","year":"2021","unstructured":"Bentz\u00a0P et al (2021) Cohort study for long-term follow-up of patients in whom the so-called \u201cmolecular classifier\u201d is used to distinguish eczema from psoriasis : Background and implementation. Hautarzt 72:354\u2013357. https:\/\/doi.org\/10.1007\/s00105-021-04774-9","journal-title":"Hautarzt"},{"key":"5148_CR28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/ddg.14850_g","volume":"20","author":"P Bentz","year":"2022","unstructured":"Bentz\u00a0P, Eyerich\u00a0K, Weisshaar\u00a0E (2022) Psoriasis oder Ekzem? Einjahrige Ergebnisse aus dem DGUV-Forschungsprojekt FB323 mit Einsatz des Molekularen Klassifikators bei Berufsdermatosen. J\u00a0Dtsch Dermatol Ges 20:1233\u20131235. https:\/\/doi.org\/10.1111\/ddg.14850_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"5148_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.02.015","author":"F Fischer","year":"2023","unstructured":"Fischer\u00a0F et\u00a0al (2023) Gene expression based molecular test as diagnostic aid for the differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded tissue, microbiopsies and tape strips. J\u00a0Invest Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2023.02.015","journal-title":"J Invest Dermatol"},{"key":"5148_CR30","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","volume":"9","author":"RJ Konrad","year":"2019","unstructured":"Konrad\u00a0RJ et al (2019) Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a\u00a0sensitive and specific novel immunoassay. Sci Rep 9:5211. https:\/\/doi.org\/10.1038\/s41598-019-41609-z","journal-title":"Sci Rep"},{"key":"5148_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger\u00a0F et al (2017) beta-Defensin 2 is a\u00a0responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J\u00a0Allergy Clin Immunol 139:923\u2013932e8. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.038","journal-title":"J Allergy Clin Immunol"},{"key":"5148_CR32","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/all.14492","volume":"75","author":"DS Bakker","year":"2020","unstructured":"Bakker\u00a0DS et al (2020) EASI p\u2011EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a\u00a0combination of serum biomarkers. Allergy 75:3287\u20133289. https:\/\/doi.org\/10.1111\/all.14492","journal-title":"Allergy"},{"key":"5148_CR33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaci.2016.04.018","volume":"138","author":"L Krause","year":"2016","unstructured":"Krause\u00a0L et\u00a0al (2016) A computational model to predict severity of atopic eczema from 30 serum proteins. J\u00a0Allergy Clin Immunol 138:1207\u20131210e2. https:\/\/doi.org\/10.1016\/j.jaci.2016.04.018","journal-title":"J Allergy Clin Immunol"},{"key":"5148_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","volume":"134","author":"N Dhingra","year":"2014","unstructured":"Dhingra\u00a0N et al (2014) Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J\u00a0Allergy Clin Immunol 134:362\u2013372. https:\/\/doi.org\/10.1016\/j.jaci.2014.03.009","journal-title":"J Allergy Clin Immunol"},{"key":"5148_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/all.14557","author":"F Lauffer","year":"2020","unstructured":"Lauffer\u00a0F et\u00a0al (2020) Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins. Allergy. https:\/\/doi.org\/10.1111\/all.14557","journal-title":"Allergy"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05148-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T17:02:38Z","timestamp":1686157358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05148-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["5148"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05148-z","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"29 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N. Garzorz-Stark und K. Eyerich sind Gr\u00fcndungsmitglieder der Firma Dermagnostix, Hamburg. K.\u00a0Technau-Hafsi gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}